G1 Therapeutics, Inc. GTHX

Set alert

Price alert · GTHX

All alert types
7.16 0.00 0.00%

As of Sep 17, 3:56 PM ET

7.14 Day range 7.16

52-week range unavailable

Open
7.15
Prev close
7.16
Mkt cap
377.22M
Vol
1.10M
Avg vol
0
EPS
0.00
P/E
0.00
Div yield
0.00%
More statistics
Low
7.14
High
7.16
Forward P/E
0.00
Beta
1.68
Short ratio
1.01
Inst. own
54.62%
Dividend
0.00
Ex-div date
Earnings
Nov 6, 2024
50-d avg
5.84
200-d avg
4.10
1y target
7.15

5D chart

Chart tools
Interval

Chart is warming up

The five-day price history for GTHX has not been loaded yet. Try again in a moment.

Discussion (6)

Sign in to join the discussion

VICKY HANUKA GTHX 3 years ago #1

Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics' Royalty on Evrysdi

-- Royalty Pharma purchases a portion of royalties on Roche's Evrysdi for
$1.0 billion upfront
-- PTC Therapeutics has option to sell rest of royalty for up to $500
million; Royalty Pharma has option to buy half of rest of royalty for up
to $250 million
-- Transaction expected to enhance long-term Adjusted Cash Receipts growth
(non-GAAP)
-- Royalty Pharma to host conference call today, Thursday, October 19 at
9:00am EDT
NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. to acquire additional royalties on Roche's Evrysdi for $1.0 billion upfront. The agreement includes options for PTC to sell up to all of its retained royalties on Evrysdi for up to $500 million or for Royalty Pharma to acquire half of such retained royalties for up to $250 million at a later date.

Lawrence Mcdonald GTHX 3 years ago #4

This stock is being milked like a cow. It is going to take news go move this up and until then it's 5.50/6.50 trading range